GSK launches $2.5 billion buyback, lifts sales target after stellar ...

3 days ago · GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion …

CouponFollow Extension

6%
OFF

GSK Launches $2.5 Billion Buyback, Lifts Sales Target After Stellar ...

2 weeks from now

3 days ago · GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion …

reuters.com

3%
OFF

GSK Beats Q4 Earnings Estimates, Lifts 2031 Sales Target - MSN

2 weeks from now

(Reuters) - GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines ...

msn.com

$2
OFF

GSK Beats On Q4 Earnings & Sales, Stock Up On Raised Long-Term …

2 weeks from now

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

yahoo.com

1%
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion …

2 weeks from now

3 days ago · Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The …

yahoo.com

3%
OFF

GSK Beats Q4 Earnings Estimates, Lifts 2031 Sales Target

2 weeks from now

3 days ago · (Reuters) - GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness …

marketscreener.com

$50
OFF

GSK Surges After Bumping Its 2031 Outlook To North Of $50 Billion

2 weeks from now

2 days ago · Specifically, GSK called for more than 40 billion pounds in 2031 sales, up from its previous outlook for north of 38 billion pounds. That translates to $50.07 billion, up from …

investors.com

$50
OFF

GSK Lifts 2031 Sales Target After Better-than-expected Q4

2 weeks from now

3 days ago · (Reuters) – GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily …

srnnews.com

£40
OFF

GSK Boosts 2031 Revenue Target To Over £40bn Following Robust …

2 weeks from now

3 days ago · Pharmaceutical titan GSK has raised its 2031 sales forecast to over £40bn, an increase from the previously projected £38bn, following a stronger-than-anticipated …

business-live.co.uk

$50
OFF

GSK Lifts 2031 Sales Target After Better-than-expected Q4

2 weeks from now

Feb 5 (Reuters) - GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its ...

lse.co.uk

3%
OFF

GSK Beats Q4 Earnings Estimates, Lifts 2031 Sales Target

2 weeks from now

3 days ago · GSK beats Q4 earnings estimates, lifts 2031 sales target. GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in …

public.com

3%
OFF

New Jersey MarketBeats | US | Cushman & Wakefield

2 weeks from now

Jan 13, 2025 · Central New Jersey’s office market showed signs of stabilization in the fourth quarter of 2024, with new leasing activity rising 8.3% from the previous quarter after two …

cushmanwakefield.com

3%
OFF

GSK Beats Q4 Earnings Estimates, Lifts 2031 Sales Target

2 weeks from now

3 days ago · (Reuters) - GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness …

globalbankingandfinance.com

$2
OFF

GSK Beats On Q4 Earnings & Sales, Stock Up On Raised Long-Term …

2 weeks from now

3 days ago · GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion. GSK Beats on …

nasdaq.com

FAQs about GSK launches $2.5 billion buyback, lifts sales target after stellar ... Coupon?

Will GSK increase its sales?

(Reuters) -GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make up for pressures on its vaccines revenue. ...

What was GSK's fourth-quarter sales?

Wednesday, GSK Plc (NYSE: GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts estimated sales of $9.58 billion. ...

Will GSK buy back 2 billion pounds of shares in 2025?

Stock Buyback: GSK also said it would buy back 2 billion pounds of shares over the next 18 months. Guidance: GSK expects 2025 sales to grow between 3% and 5%, with core earnings per share growing between 6% and 8%, including the benefit from the share buyback. ...

How will GSK perform in 2025?

(Reuters) - GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines division. ...

How did GSK plc perform in Q4 2024?

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year on a reported basis and 10% at a constant exchange rate (CER) due to increased operating expenses during the quarter. ...

Why were GSK shares up 6% at 1342 GMT?

GSK's shares were up 6% at 1342 GMT after the British drugmaker's fourth-quarter results also topped expectations. Since taking the helm in 2017, CEO Emma Walmsley has returned GSK to growth with a focus on cancer and infectious diseases to counter a combination of patent expiries and declining revenue from its best-selling medicines by 2030. ...